66
Participants
Start Date
October 19, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
BN104 monotherapy
Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
BN104 monotherapy
Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)
BN104 monotherapy - rp2d
receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)
The First Affiliated Hospital of Soochow University, Suzhou
Institut de Recherches Internationales Servier (I.R.I.S.)
INDUSTRY